Q-omics provides the consensus-scored SELENOTP1 profile across patient tissues and cancer cell-line models. SELENOTP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SELENOTP1 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SELENOTP1 RNA expression shows 15,590 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, HNSC, and ACC as cancer lineages where SELENOTP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SELENOTP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SELENOTP1 survival associations across molecular data types. SELENOTP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SELENOTP1 RNA expression–survival associations across cancer types. High SELENOTP1 expression shows unfavorable associations in LUAD and CHOL, but favorable associations in THCA, KIRC, KIRP and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for SELENOTP1 RNA expression.
This table summarizes SELENOTP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SELENOTP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SELENOTP1 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, BRCA and LUAD. The HNSC box plot shows higher SELENOTP1 RNA expression in tumor versus normal tissue (log2 FC = +0.346, t-test p < 0.001).
This table shows molecular features associated with SELENOTP1 in patient tissues and cancer cell lines. In patient samples, SELENOTP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
